Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Stopped: Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT Withdrawn before enrolling
- Stopped: SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants Recruitment suspended
- Stopped: Multimedia Aid for Genetic Testing in Gynecologic Oncology Recruitment suspended
- Notable: IVMED-85 on Pediatric Myopia Enrollment reduced: 216 → 144 participants
- Notable: CRF2 Agonist · Worsening Heart Failure Enrollment reduced: 300 → 210 participants
- Notable: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel · Prostate Cancer That Has Been Removed by Surgery Enrollment reduced: 612 → 175 participants
- Notable: Improving Information Sharing Between Family Caregivers and Home Care Aides Enrollment reduced: 100 → 20 participants
- Notable: Integrated Motivational Interviewing and Rational Emotive Behavior Therapy Intervention for Non-Suicidal Self-Injury Among Malaysian Primary School Students: A Feasibility Trial Protocol Enrollment reduced: 105 → 70 participants
- Notable: AI-Driven Multimodal Imaging Integration for Diagnosis and Prognostication of Digestive System Diseases Enrollment reduced: 5000 → 1000 participants
- Notable: Daraxonrasib and Daraxonrasib + GnP as First-line Treatment · Metastatic Pancreatic Adenocarcinoma Primary endpoint(s) modified
- Notable: SCALE KIDS · Research Study to Look at How Well a New Medicine is at Lowering Weight · Obesity Results posted: Nov 16, 2026
- Notable: S243249 Monotherapy · Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation Start date pushed from Oct 20, 2026 to Feb 1, 2027
- Notable: MR-146 · Stage I and Stage II Neurotrophic Keratopathy Primary endpoint(s) modified
- Notable: TSN1611 Treating · Advanced Solid Tumors Harboring KRAS G12D Mutation Primary completion pushed from Oct 30, 2026 to Oct 30, 2027
- Notable: Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism Results posted: Nov 16, 2026
- Notable: CPU-YL01 Injection · Chronic Hepatitis B Primary endpoint(s) modified
- Notable: UtiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy Primary and study completion dates pushed to Sep 30, 2027
- Notable: Feeding TL Trial Primary endpoint(s) modified
- Notable: RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer Recruitment opened
- Notable: Precision Administration of Anti-thymocyte Globulin With or Without Verapamil Primary endpoint(s) modified
- Notable: Single-center Study of FAPI PET Imaging and Liquid Biopsy in Bladder Cancer Primary endpoint(s) modified
- Notable: Statin Combined With Amlodipine Treats Primary Aldosteronism Primary and study completion dates pushed to Nov 15, 2026
- Notable: Delivery and Effects of THC Vaping Liquids in the Bloodstream Primary completion pushed from Mar 1, 2028 to Dec 1, 2028
- Notable: Single-Dose Hyaluronic Acid Injection · Knee Osteoarthritis Primary endpoint(s) modified
- Notable: Impact of UFPs and MNPs on Fetal Health Primary endpoint(s) modified
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates